CareDx CEO Hanna John Walter JR Sells Shares
CareDx President and CEO Hanna John Walter JR sold 100 shares of CDNA in a planned transaction.
Key Points
- CareDx's CEO Hanna John Walter JR sold 100 shares at $29.00 each on June 26, 2026, in a planned transaction.
- CareDx, Inc. has a market cap of about $1.49 billion and trades on NasdaqGM with a beta of 2.479.
- BTIG maintained a 'buy' rating on CDNA with a $28.00 target on April 29, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 26, 2026, CareDx, Inc.'s President and CEO, Hanna John Walter JR, sold 100 shares of the company on the NasdaqGM. The shares were sold at an average price of $29.00 each, amounting to a total value of $2,900. This transaction was planned under a Rule 10b5-1 trading plan.
Insider Buying and Selling at CareDx, Inc.
Hanna John Walter JR, the President and CEO of CareDx, has been active in trading the company's shares. On June 29, 2026, he conducted several transactions, including selling 39,900 shares at $29.24 in a planned sale and buying 39,900 shares at $8.20. These transactions highlight his ongoing engagement with the company's stock.
CareDx, Inc. Stock Down 43.1%
Shares of NasdaqGM:CDNA traded near $29.28 on Wednesday. CareDx, Inc. has a market capitalization of approximately $1.49 billion. The company has a forward P/E ratio of 25.41 and a beta of 2.479, indicating significant volatility. The stock's 52-week range is between $10.96 and $29.08, with moving averages of $22.35 over 50 days and $18.68 over 200 days. CareDx maintains a healthy current ratio of 3.403 and a quick ratio of 2.928, with a debt-to-equity ratio of 7.813.
$CDNA stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
CareDx reported revenue of $412.82 million, with a revenue growth of 39%. However, the company posted a net margin of -1.98% and a return on equity of -2.37%, reflecting ongoing challenges in profitability. The next earnings report is expected on August 5, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
1 analysts raised price targets.
-
EPS & revenue
EPS beat estimates by 149.6%. Revenue beat estimates by 10.8%.
-
Profit surprise
EBITDA missed by 9 percent. Operating income beat by 11 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
1 target raise.
-
Earnings quality
Gross margin up 5.0 points. Operating margin up 17.3 points. Negative free cash flow.
Earnings Call Summary
The company reported strong first quarter results with $118 million in revenue, up 39 percent year over year, beating expectations by about $11 million. Testing services grew 48 percent and each test brought in $16.60 on average. Management announced two major moves: selling the Lab Products business to focus on testing services, and acquiring Navaris to expand into viral cancer testing where they can apply their expertise in repeat monitoring and workflow automation.
Guidance CareDx expects about $456 million in revenue for 2026, up 20 percent from 2025. They also expect adjusted EBITDA of about $50 million, up 58 percent. The company is selling off its Lab Products business for $170 million in cash and acquiring Navaris, which makes cancer tests for about $34 million in revenue last year.
Good report. The company beat and showed some forward improvement, with a few meaningful caveats.
Analysts Set New Price Targets
BTIG maintained its 'buy' rating on CareDx with a price target of $28.00 on April 29, 2026. The consensus among analysts is a 'buy' rating, with a mean target price of $25.80 based on five analyst opinions.
About CareDx
CareDx, Inc. is a healthcare company specializing in diagnostic solutions to enhance outcomes for transplant patients and advance organ health. Based in Brisbane, California, the company offers a range of services, including AlloSure for kidney, heart, and lung transplants, as well as other diagnostic and management solutions for transplant recipients. Founded in 1998, CareDx employs 761 people and is led by CEO John Walter Hanna Jr.
Bottom Line
CareDx, Inc.'s CEO, Hanna John Walter JR, has been active in trading shares, with recent sales and purchases demonstrating his involvement. The company's stock is volatile, with a high beta and significant fluctuations over the past year. Analysts remain optimistic, maintaining a 'buy' rating with a target price reflecting potential growth. Investors should note that insider transactions like these are planned and part of routine financial management.
Get CareDx, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CDNA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.